{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:51:39Z","timestamp":1790268699590,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck & Co., Inc. | Merck Sharp and Dohme","doi-asserted-by":"publisher","award":["MISP 55746"],"award-info":[{"award-number":["MISP 55746"]}],"id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Data regarding the efficacy and tolerability of elbasvir\/grazoprevir (EBR\/GZR) for East-Asian hepatitis C virus genotype 1b (HCV GT1b) patients receiving hemodialysis were limited. We prospectively recruited 40 HCV GT1b hemodialysis patients who received EBR\/GZR for 12 weeks at 6 academic centers in Taiwan. The efficacy endpoints were sustained virologic response 12 weeks off-therapy (SVR<jats:sub>12<\/jats:sub>) by intention-to-treat (ITT) modified ITT (mITT) analyses. Patients\u2019 baseline characteristics, early viral kinetics and HCV resistance-associated substitutions (RASs) at HCV non-structural 3 and 5\u2009A (NS3 and NS5A) regions potentially affecting SVR<jats:sub>12<\/jats:sub>were analyzed. The tolerability for EBR\/GZR was also assessed. The SVR<jats:sub>12<\/jats:sub>rates by ITT and mITT analyses were 95% (38 of 40 patients; 95% confidence interval (CI): 83.5\u201398.6%) and 100% (38 of 38 patients; 95% CI: 90.8\u2013100%), respectively. Patients\u2019 baseline characteristics, on-treatment viral decline, and baseline HCV RASs did not affect SVR<jats:sub>12<\/jats:sub>. All patients tolerated treatment well. Among 5 patients who had serious adverse events (AEs) including one death due to on-treatment suicide and the other death due to off-therapy acute myocardial infarction, none of these events were judged related to EBR\/GZR. The common AEs included upper respiratory tract infection (7.5%), fatigue (5.0%) and anorexia (5.0%). Nine (22.5%) and 8 (20.0%) patients had on-treatment hemoglobin levels of 9.0\u201310.0\u2009g\/dL and 7.0\u20139.0\u2009g\/dL. Three (7.5%) patients had on-treatment elevated alanine aminotransferase (ALT) quotient &gt; 2.5, in whom one (2.5%) had EBR\/GZR-induced late ALT elevation. No patients developed hyperbilirubinemia or hepatic decompensation. In conclusion, treatment with EBR\/GZR is effective and well-tolerated for East-Asian HCV GT1b patients receiving hemodialysis.<\/jats:p>","DOI":"10.1038\/s41598-020-66182-8","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T10:05:16Z","timestamp":1591610716000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Elbasvir\/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3622-9707","authenticated-orcid":false,"given":"Chen-Hua","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9030-6086","authenticated-orcid":false,"given":"Cheng-Yuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jen","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5506-4293","authenticated-orcid":false,"given":"Wei-Yu","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Shun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Kuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsueh-Chou","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Pang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Uei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Chao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6747-7941","authenticated-orcid":false,"given":"Tung-Hung","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8082-7144","authenticated-orcid":false,"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Jer","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding-Shinn","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-7952","authenticated-orcid":false,"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"key":"66182_CR1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000355615","volume":"38","author":"DA Goodkin","year":"2013","unstructured":"Goodkin, D. A. et al. Hepatitis C infection is very rarely treated among hemodialysis patients. Am. J. Nephrol. 38, 405\u2013412 (2013).","journal-title":"Am. J. Nephrol."},{"key":"66182_CR2","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1681\/ASN.2016010030","volume":"27","author":"M Ladino","year":"2016","unstructured":"Ladino, M. et al. Hepatitis C virus infection in chronic kidney disease. J. Am. Soc. Nephrol. 27, 2238\u20132246 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"66182_CR3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.1440-1746.2010.06488.x","volume":"26","author":"CH Liu","year":"2011","unstructured":"Liu, C. H. & Kao, J. H. Treatment of hepatitis C virus infection in patients with end-stage renal disease. J. Gastroenterol. Hepatol. 26, 228\u2013239 (2011).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"66182_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41581-018-0081-8","volume":"15","author":"S Pol","year":"2019","unstructured":"Pol, S. et al. Hepatitis C virus and the kidney. Nat. Rev. Nephrol. 15, 73\u201386 (2019).","journal-title":"Nat. Rev. Nephrol."},{"key":"66182_CR5","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1093\/ndt\/gfn684","volume":"24","author":"DW Johnson","year":"2009","unstructured":"Johnson, D. W. et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol. Dial. Transplant. 24, 1598\u20131603 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"66182_CR6","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/hep.29192","volume":"66","author":"TS Lai","year":"2017","unstructured":"Lai, T. S. et al. REVEAL-HCV Study Group. Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study. Hepatology. 66, 784\u2013793 (2017).","journal-title":"Hepatology."},{"key":"66182_CR7","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1365-2893.2012.01633.x","volume":"19","author":"F Fabrizi","year":"2012","unstructured":"Fabrizi, F. et al. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J. Viral Hepat. 19, 601\u2013607 (2012).","journal-title":"J. Viral Hepat."},{"key":"66182_CR8","unstructured":"Geneva: World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. 2018 Licence: BY-NC-SA3.0 IGO. Access at, https:\/\/www.who.int\/hepatitis\/publications\/hepatitis-c-guidelines-2018\/en\/ on 18 December 2019."},{"key":"66182_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1001\/jama.2019.5353","volume":"322","author":"K Marks","year":"2019","unstructured":"Marks, K. & Naggie, S. Management of hepatitis C in 2019. JAMA. 322, 355\u2013356 (2019).","journal-title":"JAMA."},{"key":"66182_CR10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","volume":"54","author":"BJ Kirby","year":"2015","unstructured":"Kirby, B. J. et al. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin. Pharmacokinet. 54, 677\u2013690 (2015).","journal-title":"Clin. Pharmacokinet."},{"key":"66182_CR11","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jhep.2019.05.028","volume":"71","author":"SM Borgia","year":"2019","unstructured":"Borgia, S. M. et al. Sofosbuvir\/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J. Hepatol. 71, 660\u2013665 (2019).","journal-title":"J. Hepatol."},{"key":"66182_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00228-018-2585-3","volume":"75","author":"L Caro","year":"2019","unstructured":"Caro, L. et al. Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment. Eur. J. Clin. Pharmacol. 75, 665\u2013675 (2019).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"66182_CR13","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","volume":"386","author":"D Roth","year":"2015","unstructured":"Roth, D. et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 386, 1537\u20131545 (2015).","journal-title":"Lancet."},{"key":"66182_CR14","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.kint.2018.02.019","volume":"94","author":"L Alric","year":"2018","unstructured":"Alric, L. et al. Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4\/5 severe chronic kidney disease is safe and effective. Kidney. Int. 94, 206\u2013213 (2018).","journal-title":"Kidney. Int."},{"key":"66182_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.antiviral.2018.10.003","volume":"159","author":"E Ogawa","year":"2018","unstructured":"Ogawa, E. et al. Kyushu University Liver Disease Study (KULDS) Group. Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease. Antiviral. Res. 159, 143\u2013152 (2018).","journal-title":"Antiviral. Res."},{"key":"66182_CR16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00535-018-1495-6","volume":"54","author":"G Suda","year":"2019","unstructured":"Suda, G. et al. NORTE Study Group. Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection. J. Gastroenterol. 54, 78\u201386 (2019).","journal-title":"J. Gastroenterol."},{"key":"66182_CR17","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/jgh.14447","volume":"34","author":"M Atsukawa","year":"2019","unstructured":"Atsukawa, M. et al. Efficacy and safety of elbasvir\/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study. J. Gastroenterol. Hepatol. 34, 364\u2013369 (2019).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"66182_CR18","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1128\/JCM.03548-14","volume":"53","author":"CH Liu","year":"2015","unstructured":"Liu, C. H. et al. Comparison of Abbott RealTime HCV Genotype II with Versant Line Probe Assay 2.0 for hepatitis C virus genotyping. J. Clin. Microbiol. 53, 1754\u20131757 (2015).","journal-title":"J. Clin. Microbiol."},{"key":"66182_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-137-1-200207020-00006","volume":"137","author":"D Prati","year":"2002","unstructured":"Prati, D. et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med. 137, 1\u201310 (2002).","journal-title":"Ann. Intern. Med."},{"key":"66182_CR20","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2215\/CJN.04320510","volume":"6","author":"CH Liu","year":"2011","unstructured":"Liu, C. H. et al. Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients. Clin. J. Am. Soc. Nephrol. 6, 1057\u20131065 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"66182_CR21","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1053\/j.gastro.2016.10.017","volume":"152","author":"TE Komatsu","year":"2017","unstructured":"Komatsu, T. E. et al. Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of elbasvir and grazoprevir. Gastroenterology. 152, 586\u2013597 (2017).","journal-title":"Gastroenterology."},{"key":"66182_CR22","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/apt.15011","volume":"48","author":"CH Liu","year":"2018","unstructured":"Liu, C. H. et al. Comorbidities, concomitant medications, and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan. Aliment. Pharmacol. Ther. 48, 1290\u20131300 (2018).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"66182_CR23","doi-asserted-by":"publisher","first-page":"ofx028","DOI":"10.1093\/ofid\/ofx028","volume":"4","author":"CH Liu","year":"2017","unstructured":"Liu, C. H. et al. Hepatitis B virus reactivation in patients receiving interferon-free direct-acting antiviral agents for chronic hepatitis C virus infection. Open. Forum. Infect. Dis. 4, ofx028 (2017).","journal-title":"Open. Forum. Infect. Dis."},{"key":"66182_CR24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.7326\/0003-4819-159-11-201312030-00005","volume":"159","author":"CH Liu","year":"2013","unstructured":"Liu, C. H. et al. Pegylated interferon-\u03b12a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann. Intern. Med. 159, 729\u2013738 (2013).","journal-title":"Ann. Intern. Med."},{"key":"66182_CR25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/jgh.14509","volume":"34","author":"L Wei","year":"2019","unstructured":"Wei, L. et al. C-CORAL Investigators. Efficacy and safety of elbasvir\/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study. J. Gastroenterol. Hepatol. 34, 12\u201321 (2019).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"66182_CR26","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","volume":"370","author":"F Poordad","year":"2014","unstructured":"Poordad, F. et al. ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N. Engl. J. Med. 370, 1973\u20131982 (2014).","journal-title":"N. Engl. J. Med."},{"key":"66182_CR27","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1111\/jgh.14672","volume":"34","author":"CH Liu","year":"2019","unstructured":"Liu, C. H. et al. Paritaprevir\/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis. J. Gastroenterol. Hepatol. 34, 1977\u20131983 (2019).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"66182_CR28","first-page":"562A","volume":"62","author":"GM Dusheiko","year":"2015","unstructured":"Dusheiko, G. M. et al. Safety and tolerability of grazoprevir\/elbasvir in patients with chronic hepatitis C (HCV) infection: integrated analysis of phase 2-3 trials. Hepatology. 62, 562A (2015).","journal-title":"Hepatology."},{"key":"66182_CR29","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","volume":"3","author":"MM M\u00fccke","year":"2018","unstructured":"M\u00fccke, M. M. et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet. Gastroenterol. Hepatol. 3, 172\u2013180 (2018).","journal-title":"Lancet. Gastroenterol. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66182-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66182-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66182-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T02:48:09Z","timestamp":1696214889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-66182-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["66182"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-66182-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,8]]},"assertion":[{"value":"22 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Chen-Hua Liu has received compensations as a member of the scientific advisory board for Abbvie and Gilead Sciences. He has consulted for Abbott, AbbVie, Gilead Sciences, and Merck Sharp & Dohme, and received compensations. He also has received research grants from Abbvie, Gilead Sciences, and Merck Sharp & Dohme. Dr. Chun-Jen Liu has received compensations as a member of the scientific advisory board for Gilead Sciences and Merck Sharp & Dohme. He has consulted for AbbVie, Gilead Sciences, and Merck Sharp & Dohme, and received compensations. He also has received research grant from Gilead Sciences. Dr. Jia-Horng Kao has received compensations as a member of the scientific advisory board for Abbott, AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, and Roche. He has consulted for Abbott, AbbVie, Bayer, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, and Roche and received compensations. Dr. Ding-Shinn Chen has received compensations as a member of the scientific advisory board for Abbvie, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, and Novartis. Dr. Pei-Jer Chen has received compensations as a member of the scientific advisory board for AbbVie, Novartis, and Roche. All other authors declare no potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9180"}}